Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Georgetown University
Study ID
NCT06664541
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Determine knowledge, attitudes, and beliefs among adult patients, and parents of pediatric patients, with transfusion dependent beta-thalassemia and sickle cell disease toward gene therapy to treat their or their child's illness, and to assess the likely impact of gene therapy on patients' quality of life.

Key Dates

Start date
Oct 1, 2024
Status verified
Oct 2024
Primary completion
Oct 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Group 1
    Patients or parents of pediatric patients diagnosed with beta-thalassemia or sickle cell disease and eligible to receive treatment for their disease with gene therapy.

Primary Outcome Measure

Quality of Life [ Time Frame: Past 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Georgetown University Medical CenterWashington D.C.District of Columbia20007-

Find similar trials in Washington D.C., DC

By condition
Sickle cell disease
By research site
Georgetown University Medical Center· Washington D.C., DC

Related Studies